Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomics England Pilot Project, |
RCV001542738 | SCV001760118 | likely pathogenic | Optic atrophy with or without deafness, ophthalmoplegia, myopathy, ataxia, and neuropathy | no assertion criteria provided | clinical testing | ||
Prevention |
RCV004541988 | SCV004777773 | likely pathogenic | OPA1-related disorder | 2024-03-01 | no assertion criteria provided | clinical testing | The OPA1 c.1728_1734del7 variant is predicted to result in a frameshift and premature protein termination (p.Glu576Aspfs*7). To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in OPA1 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |